Christopher Simon - 16 May 2025 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Reporting relationship: President & CEO, Director
Issuer ticker: HAE
Reported as of: 16 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 May 2025, 17:10:55 UTC
Prior SEC filing: 19 May 2025
Next SEC filing: 27 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Thomas V. Powers, attorney-in-fact for Mr. Simon

Key filing fact

Christopher Simon filed Form 4 for HAEMONETICS CORP (HAE) on 20 May 2025.

Key facts

This page summarizes Christopher Simon's Form 4 filing for HAEMONETICS CORP (HAE).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 20 May 2025, 17:10.

Change

Previous filing in this sequence was filed on 19 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001674993 Primary reporting owner

Simon, Christopher

Relationship: President & CEO, Director
Address: 125 SUMMER STREET, BOSTON
Signature: /s/ Thomas V. Powers, attorney-in-fact for Mr. Simon
Signature date: 20 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HAE transaction

Common Stock

Award

Transaction value
Shares: +21,405
Change %: +6.8%
Price
Shares after: 335,112
Date: 16 May 2025
Ownership: Direct
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HAE transaction Derivative

Non-qualified Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +46,342
Change %
Price: $0.000000
Shares after: 46,342
Date: 16 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 46,342
Exercise price: $70.31
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

Footnote F2

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Footnote F3

This number includes unvested RSUs previously reported.

Footnote F4

Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.